Last reviewed · How we verify
NCT04490590
A Clinical Trial of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma
Phase 4 trial testing Chidamide+ Etoposide in NK/T-Cell Lymphoma in 30 participants. Status unknown.
1 October 2020
Quick facts
| Lead sponsor | Mingzhi Zhang |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 1 October 2016 |
| Primary completion | 1 October 2020 |
| Estimated completion | 1 October 2021 |
| Sites | 1 location across China |
Drugs / interventions tested
- Chidamide+ Etoposide — full drug profile →
Conditions studied
- NK/T-Cell Lymphoma — all drugs for NK/T-Cell Lymphoma →
Sponsor
Mingzhi Zhang — full company profile →
Who can join
Adults 10 to 65, any sex, with NK/T-Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To observe the safety, tolerability and clinical effects of Chidamide Combined With Etoposide in Relapsed or Refractory NK/T-cell Lymphoma.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment.
Sun Y, Hong JH, Ning Z, Pan D, et al · · 2022 · cited 58× · PMID 36120308 · DOI 10.3389/fphar.2022.932914 -
Novel targeted therapies of T cell lymphomas.
Iżykowska K, Rassek K, Korsak D, Przybylski GK, et al · · 2020 · cited 49× · PMID 33384022 · DOI 10.1186/s13045-020-01006-w -
The Status and Prospects of Epigenetics in the Treatment of Lymphoma.
Liu J, Li JN, Wu H, Liu P. · · 2022 · cited 10× · PMID 35463343 · DOI 10.3389/fonc.2022.874645
Verify or expand the search:
- PubMed search for NCT04490590
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Mingzhi Zhang trials
Trials by the same sponsor.
- NCT06647329 — CAR-T Technology for Recurrent/Refractory Malignant Hematological and Lymphatic Tumors · Phase 1 · not yet recruiting
- NCT06683885 — A Prospective Clinical Study of the Combination Therapy of Obutinib or Decitabine with Rituximab, Cyclophosphamide, and · Phase 1, PHASE2 · recruiting
- NCT06559553 — "Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCL · Phase 1, PHASE2 · recruiting
- NCT04831658 — A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervou · Phase 1, PHASE2 · unknown
- NCT04083066 — Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous Sys · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04490590 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mingzhi Zhang
- Last refreshed: 29 July 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04490590.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing